Virpax Pharmaceuticals (VRPX) surged in recent Friday trading after the specialty medications company said injections of its Probudur drug candidate into tissue surrounding an incisional wound provided both immediate and extended pain relief in minipigs during preclinical testing to determine optimal dosing ranges.
All of the minipigs in the study showed positive tolerance to Probudur and had no adverse effects. Based on the positive results, Virpax said it would continue to work on developing human trials for Probudur as part of an eventual investigational new drug application.
The company's shares were up 47% in recent trading Friday.
Price: 0.83, Change: +0.26, Percent Change: +47.50
Comments